Who are FXIII Concentrate (Human)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fibrinogen Concentrate Human, Plasma-derived FVIII/VWF concentrate, Prothrombin Complex Concentrate, Human.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fxiii-concentrate-human.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

FXIII Concentrate (Human) — Competitive Intelligence Brief

FXIII Concentrate (Human) (FXIII Concentrate (Human)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Coagulation factor concentrate. Area: Hematology.

phase 3 Coagulation factor concentrate Coagulation Factor XIII (F13A1) Hematology Biologic Live · refreshed every 30 min

Target snapshot

FXIII Concentrate (Human) (FXIII Concentrate (Human)) — CSL Behring. FXIII Concentrate replaces deficient coagulation Factor XIII to restore normal blood clot cross-linking and stabilization.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
FXIII Concentrate (Human) TARGET	FXIII Concentrate (Human)	CSL Behring	phase 3	Coagulation factor concentrate	Coagulation Factor XIII (F13A1)
Fibrinogen Concentrate Human	Fibrinogen Concentrate Human	IRCCS Policlinico S. Donato	marketed	Coagulation factor concentrate	Fibrinogen (Factor I)
Plasma-derived FVIII/VWF concentrate	Plasma-derived FVIII/VWF concentrate	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	marketed	Coagulation factor concentrate	Factor VIII and von Willebrand Factor
Prothrombin Complex Concentrate, Human	Prothrombin Complex Concentrate, Human	SHI Jia	marketed	Coagulation factor concentrate	Clotting factors II, VII, IX, X (vitamin K-dependent factors)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Coagulation factor concentrate class)

CSL Behring · 1 drug in this class
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · 1 drug in this class
IRCCS Policlinico S. Donato · 1 drug in this class
SHI Jia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). FXIII Concentrate (Human) — Competitive Intelligence Brief. https://druglandscape.com/ci/fxiii-concentrate-human. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab